4 ms·
I can give a hypothetical reason why specifically might not work (disclaimer: my PhD thesis is in this field). In most Type I diabetics, the autoantigen (as in
by dnautics 12y ago
I can give a hypothetical reason why specifically might not work (disclaimer: my PhD thesis is in this field). In most Type I diabetics, the autoantigen (as in the protein that is the target of immune attack) is this peptide called amylin. This peptide is a generally problematic peptide - it's metastable - and in Type II diabetics it forms plaques. Interestingly, mice and rats have amylin, but unlike most other mammals, it's not metastable[0]. I would not be surprised if in NOD (non-obese-diabetic) mice it's NOT the autoantigen.
Based on different protein targetting, the mechanism of beta-cell killing in NOD mice might not have exactly the same autoimmune interactions, and a rejuvenation strategy might not work in humans quite the same way.
It's not entirely clear to me when they plan on doing therapeutic intervention for children with Type I diabetes; by the time first symptoms show up it may be too late (unlike the mice where they knew when/that it would happen).
Finally, it's a bit odd to me that they didn't look through health records of existing type I diabetes patients that have been incidentally prescribed Verapamil. There should be some usable data that hints at the possible usefulness of this strategy, unless the patients were treated for hypertension much later in life than getting diabetes (very likely), aka too late to do anything about it.
[0]mice and rats are weird, they also have two copies of the insulin gene. One of the copies has an amino acid that is absolutely conserved across all vertebrates substituted for a substantially different one.
[1] bonus: rats also don't have gall bladders.
[2] bonus 2: While I was working on diabetes model systems in the lab, we had lots of verapamil floating around, because my boss had this crazy idea that verapimil would fix a whole category of diseases (calcium homeostasis is important for protein folding in the endoplasmic reticulum).
- bigtunacan 12y agoNo PhD here, but IAMA T1D. I noticed from the actual study that candidates for the trial must be within 3 months of diagnosis to even be considered; so it seems they are trying to screen and find only those people who have just recently developed diabetes and reverse it early in the process. In a sense this is sort of like catching a soon to be T2D in the pre-diabetic phase and telling them to eat less and run more. (There is no offense intended in that previous statement; with an obese pre-diabetic (type 2) it is possible to stop the disease before things are too late through exercise and diet, this is not the case in with a Type 1). This makes me question if this is an effective treatment ONLY when caught early; or if it could be useful for long time diabetics like myself. Also this treatment addresses beta cell replacement which is one side, but it doesn't address the autoimmune side which is actually causing the beta cell destruction in the first place. So would this be a lifetime pill that is taken to continuously build new beta cells? As I see it in the autoimmune T1D case as the beta cells remain under attack this would not be a "cure" per se, but rather an ongoing treatment that would result in an overall better outcome and quality of life for a diabetic (given it works at all).
- dnautics 12y agoyou pretty much nailed all of my concerns about this (especially the pernicious concern about maintenance drugs), but if it works, hey, that's better than nothing.
- bigtunacan 12y agoYeah; if I could take a pill a day like the T2D crowd with Metformin I would prefer that any day to insulin therapy.
- deleted 12y ago[deleted]